Summit Therapeutics (SMMT) Change in Receivables (2019 - 2023)
Summit Therapeutics (SMMT) posted Change in Receivables of -$3000.0 for Q3 2023, up 50.0% on a QoQ basis from -$6000.0 in Q2 2023, and up 99.76% year-over-year from -$1501.8 in Q3 2022.
Summit Therapeutics (SMMT) Change in Receivables (2019 - 2023) Analysis & Trends
Summit Therapeutics' Change in Receivables history runs 5 years deep, the most recent figure standing at -$3000.0 for Q3 2023.
- Quarterly Change in Receivables rose 99.76% year-over-year to -$3000.0 in Q3 2023, while the trailing twelve-month figure through Jun 2024 was -$3000.0 (up 98.25% YoY) and the FY2023 annual result came in at -$359000.0, up 63.18% from the prior year.
- Change in Receivables was -$3000.0 for Q3 2023 at Summit Therapeutics, up from -$6000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $3.5 million in Q3 2020 and bottomed at -$3.7 million in Q4 2020.
- A 5-year average of -$193562.5 and a median of -$178000.0 in 2023 frame the typical range for Change in Receivables.
- Peak annual rise in Change in Receivables reached 251.5% in 2022, while the deepest fall reached 499.12% in 2022.
- Summit Therapeutics' Change in Receivables stood at -$2.7 million in 2019, then plunged by 37.3% to -$3.7 million in 2020, then jumped by 74.76% to -$932000.0 in 2021, then soared by 251.5% to $1.4 million in 2022, then sank by 100.21% to -$3000.0 in 2023.
- Business Quant data shows SMMT's Change in Receivables at -$3000.0 in Q3 2023, -$6000.0 in Q2 2023, and -$350000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Summit Therapeutics | 10.60 Bn | 10.00 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -3,000.00 |
| Sep 30, 2023 | -3,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | -350,000.00 |
| Mar 31, 2023 | -350,000.00 |
| Dec 31, 2022 | 1.41 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | -1.23 Mn |
| Sep 30, 2022 | -1.23 Mn |
| Jun 30, 2022 | -705,000.00 |
| Jun 30, 2022 | -705,000.00 |
| Mar 31, 2022 | -455,000.00 |
| Mar 31, 2022 | -455,000.00 |
| Dec 31, 2021 | -932,000.00 |
| Dec 31, 2021 | -932,000.00 |
| Sep 30, 2021 | 1.37 Mn |
| Sep 30, 2021 | 1.37 Mn |
| Jun 30, 2021 | 590,000.00 |
| Jun 30, 2021 | 590,000.00 |